Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

This study is testing whether a GLP-1 receptor agonist — the same class of medication used for weight loss and diabetes (like semaglutide) — can also improve asthma symptoms in people who are obese. Obesity-related asthma is often harder to control with standard inhalers alone, and weight loss may help reduce airway inflammation. **You may be eligible if...** - You are 18 or older - You have obesity (BMI of 30 or higher, or 27+ with a weight-related condition) - You have been diagnosed with asthma by a doctor - Your asthma is persistent and requires at least a medium-dose daily inhaled corticosteroid - Your asthma symptoms are not well controlled (ACQ-6 score of 1.5 or higher) - You have evidence of asthma on breathing tests (bronchodilator response or airway hyperresponsiveness) **You may NOT be eligible if...** - You do not have obesity - Your asthma is well-controlled on current medications - You are pregnant or planning to become pregnant - You have significant heart, kidney, or liver disease that would make GLP-1 therapy unsafe - You are taking medications incompatible with the study drug Talk to your doctor to see if this trial is right for you.